Search clinical trials for: anlotinib, fulvestrant

Total 1855 results

Cancer Institute and Hospital, Chinese Academy...

Unknown

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

Lung Cancer
Zhejiang Cancer Hospital

Recruiting

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Breast Neoplasm Female

China
Sun Yat-sen University

Recruiting

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Breast Cancer

China
Lyudmila Bazhenova, M.D.
AstraZeneca

Terminated

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Translational Oncology Research International
National Cancer Institute (NCI)

Completed

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Paraganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, Malignant

China
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
First Hospital of Shijiazhuang City

Unknown

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma | Small Cell Lung Cancer | Lung Neoplasm

China
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Peng Yuan

Completed

Anlotinib in Metastatic HER2 Negative Breast Cancer

Breast Neoplasm | Antineoplastic Agents | Anlotinib

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Hunan Cancer Hospital
Fuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...

Recruiting

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Cervical Cancer
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Genor Biopharma Co., Ltd.

Recruiting

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Event-free Lifetime

China
Zhejiang Cancer Hospital

Recruiting

Anlotinib to Malignant Brainstem Glioma

Glioma | Malignant Brain Stem Tumor

China
Feng Wang

Completed

Anlotinib Retrospective Study for Esophageal Cancer

Esophageal Neoplasms

China
The First Affiliated Hospital with Nanjing Medical...
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaborators

Unknown

Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC (CSOAIMTOAN)

Nonsmall Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Advanced Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

Recurrent Small Cell Lung Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Adenocarcinoma | Recurrent Disease | Head and Neck Carcinoma | Distantly Metastatic Malignant Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Renal Cell Carcinoma

China
Xinhua Hospital, Shanghai Jiao Tong University...

Completed

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
The First Hospital of Jilin University

Recruiting

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Breast Cancer

China
Anyang Tumor Hospital

Recruiting

Anlotinib for Esophageal Cancer (AFEC)

Esophageal Cancer

China
Guangxi Zhuang Autonomous Region People's Hospital

Recruiting

Anlotinib for Hepatocellular Carcinoma (AFHC)

Liver Neoplasms

China
Shanghai Changzheng Hospital

Recruiting

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Advanced Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase II Study of Anlotinib in STS Patients (ALTN/STS)

Cancer

China
Second Affiliated Hospital, School of Medicine,...

Unknown

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Ovarian Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC) (ATAHC)

Cancer of Liver
Nanjing First Hospital, Nanjing Medical University

Recruiting

A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial (EASOAIPPGL)

Advanced or Metastatic Paraganglioma/ Pheochromocytoma

China
Sun Yat-sen University

Completed

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Nasopharyngeal Carcinoma

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Terminated

Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Chronic Graft-versus-host-disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Neoplasm of Bone

China
First Affiliated Hospital of Wenzhou Medical University

Unknown

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

Non-Small-Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Gastroenteropancreatic Neuroendocrine Tumor G3

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib in Patients With Hepatocellular Carcinoma (ALTER0802)

Hepatocellular Carcinoma

China

Search clinical trials for: anlotinib, fulvestrant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations